Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.
Colorectal Adenocarcinoma
DRUG: Temozolomide (TMZ)|DRUG: Cisplatin|DRUG: Nivolumab
Response, will be evaluated in this study using the new international criteria proposed in RECIST 1.1 \[Eur J Ca 45:228-247, 2009\]. Changes in the largest diameter (unidimensional measurement) of the tumor and the shortest diameter of malignant lymph nodes are used with the RECIST criteria., 1 year
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.